\BOOKMARK [1][-]{section.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.2}{Methods}{}% 2
\BOOKMARK [2][-]{subsection.2.1}{Dataset and features}{section.2}% 3
\BOOKMARK [2][-]{subsection.2.2}{Problem formulation}{section.2}% 4
\BOOKMARK [2][-]{subsection.2.3}{Data preparing}{section.2}% 5
\BOOKMARK [3][-]{subsubsection.2.3.1}{Similarity matrix calculation}{subsection.2.3}% 6
\BOOKMARK [3][-]{subsubsection.2.3.2}{Integration drug similarity matrices}{subsection.2.3}% 7
\BOOKMARK [3][-]{subsubsection.2.3.3}{Input matrix format}{subsection.2.3}% 8
\BOOKMARK [2][-]{subsection.2.4}{Devising of Recommender System}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.5}{Selecting and training model on known interactions}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.6}{Selecting model}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.7}{Selecting and training model on known and unknown interactions}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.8}{Selecting final model}{section.2}% 13
\BOOKMARK [1][-]{section.3}{Result and discussion}{}% 14
\BOOKMARK [2][-]{subsection.3.1}{Assessment}{section.3}% 15
\BOOKMARK [3][-]{subsubsection.3.1.1}{First case: 10-fold CV without unknown interactions}{subsection.3.1}% 16
\BOOKMARK [3][-]{subsubsection.3.1.2}{Second case: 10-fold CV with unknown interactions}{subsection.3.1}% 17
\BOOKMARK [1][-]{section.4}{Evaluation criteria}{}% 18
\BOOKMARK [1][-]{section.5}{Comparison of results}{}% 19
\BOOKMARK [1][-]{section.6}{Conclusions}{}% 20
\BOOKMARK [2][-]{subsection.6.1}{Figures}{section.6}% 21
\BOOKMARK [3][-]{subsubsection.6.1.1}{Permission to Reuse and Copyright}{subsection.6.1}% 22
\BOOKMARK [2][-]{subsection.6.2}{Tables}{section.6}% 23
\BOOKMARK [1][-]{section.7}{Nomenclature}{}% 24
\BOOKMARK [2][-]{subsection.7.1}{Resource Identification Initiative}{section.7}% 25
\BOOKMARK [2][-]{subsection.7.2}{Life Science Identifiers}{section.7}% 26
\BOOKMARK [1][-]{section.8}{Additional Requirements}{}% 27
